Particle Size News and Research

RSS

Liu Laboratory at Augusta University studies exosomes using Particle Metrix’s ZetaView

Particle Metrix, developers of versatile particle characterization solutions for the life sciences, report on the work in the Liu Laboratory at Augusta University which is studying exosomes where size and concentration are critical parameters.

4 Apr 2016

Advances in the field of MPI: an interview with Professor Kannan Krishnan

In around 2004, there was a Phillips paper that discussed a new imaging technique called MPI. At that time, I had an eager, promising graduate student named Matt Ferguson who wanted a project, so I asked him to take a look.

From Bruker BioSpin - NMR, EPR and Imaging 1 Mar 2016

UAB researchers use Malvern’s NanoSight NS300 system to figure out role of exosomes in disease transmission

Data measured using the NanoSight NS300 from Malvern Instruments is providing new insights into the role of exosomes in diseases such as cancer, arthritis, Alzheimer’s disease and cystic fibrosis, in pioneering research at the University of Alabama - Birmingham (UAB).

23 Feb 2016

Insights into exosomes role in disease transmission gained using NanoSight from Malvern

Data measured using the NanoSight NS300 from Malvern Panalytical is providing new insights into the role of exosomes in diseases such as cancer, arthritis, Alzheimer’s disease and cystic fibrosis, in pioneering research at the University of Alabama - Birmingham (UAB).

From Malvern Panalytical 28 Jan 2016

Using centrifugal elutriation and flow cytometry to answer biological questions: an interview with Peter Lopez

Flow Cytometry, the measurement of various cellular characteristics as they flow through a measuring apparatus, has so many applications.

From Beckman Coulter Life Sciences - Centrifugation 27 Jan 2016

Using stem cells to tackle CNS disorders: an interview with Dr Stefano Pluchino

My laboratory’s long standing interest is the study of the signaling capabilities of stem cells, both under homeostatic conditions

From Beckman Coulter Life Sciences - Flow Cytometry 5 Jan 2016

Egalet submits NDA for ARYMO ER (morphine sulfate) extended-release tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the company has submitted a new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

15 Dec 2015

New method helps determine titanium nanoparticles in sunscreen products

Loads of cosmetics like sunscreen lotions contain titanium dioxide. These nanoparticles are contentious. Experts suspect they may have harmful effects on people and the environment.

3 Aug 2015

Egalet reports top-line results from Category 3 HAL study of Egalet-002

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

30 Jun 2015

Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

Egalet Corporation today announced positive results from a Category 3 intranasal human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

29 Jun 2015

‘Unsurpassed protein SEC’: OMNISEC delivers accurate information with minimal sample

In a new webinar ‘Unsurpassed protein SEC using the latest innovation in advanced detection, OMNISEC’, experts from Malvern Instruments demonstrate how the OMNISEC size exclusion chromatography (SEC) system supports efficient screening early in the drug development pipeline by enabling precise characterization with minimal sample volumes.

5 Jun 2015

Egalet announces top-line results from Egalet-002 study in moderate drinkers

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a randomized, four-way crossover alcohol-interaction study in healthy male and female moderate drinkers with Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

4 Jun 2015

Category 1 findings support robust abuse-deterrent features of Egalet-002 for management of severe pain

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced positive top-line results from Category 1 abuse-deterrent studies for Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

1 Jun 2015

MIT researchers find way to develop implantable devices that can avoid scar-tissue buildup

Biomedical devices that can be implanted in the body for drug delivery, tissue engineering, or sensing can help improve treatment for many diseases. However, such devices are often susceptible to attack by the immune system, which can render them useless.

19 May 2015

More research needed to explore toxicity of cellulose nanocrystals, says Virginia Tech scientist

Are cellulose nanocrystals harmful to human health? The answer might depend on the route of exposure, according to a review of the literature by a Virginia Tech scientist, but there have been few studies and many questions remain.

12 Mar 2015

Analytical strategies that support OSD formulation: A new whitepaper from Malvern Instruments

A new whitepaper from Malvern Panalytical provides detailed guidance on the analytical technologies that help to accelerate oral solid dosage (OSD) product formulation to a successful conclusion.

From Malvern Panalytical 12 Feb 2015

Anti-cancer nanomedicines with smaller sizes exhibit enhanced performance in vivo, show studies

Nanomedicines consisting of nanoparticles for targeted drug delivery to specific tissues and cells offer new solutions for cancer diagnosis and therapy.

17 Oct 2014

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study.

30 Sep 2014

NRL scientists develop novel one-step process to form oxide nanoparticles

Scientists at the U.S. Naval Research Laboratory Materials Science and Technology Division have developed a novel one-step process using, for the first time in these types of syntheses, potassium superoxide (KO2) to rapidly form oxide nanoparticles from simple salt solutions in water.

25 Sep 2014

Researchers made important step towards creating medical nanorobots

Researchers from the Institute of General Physics of the Russian Academy of Sciences, the Institute of Bioorganic Chemistry of the Russian Academy of Sciences and MIPT have made an important step towards creating medical nanorobots.

20 Aug 2014